BISOPROLOL FUMARATE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and renin release from kidneys.
| Metabolism | Primarily hepatic via CYP2D6 and CYP3A4; minor renal excretion of unchanged drug. |
| Excretion | Approximately 50% excreted unchanged in urine; remainder metabolized in liver to inactive metabolites, then renally excreted. Fecal excretion is negligible (<2%). Total renal clearance accounts for ~60-70% of elimination. |
| Half-life | Terminal elimination half-life is 9–12 hours (mean 11 hours), allowing once-daily dosing. Half-life may be prolonged in renal impairment (creatinine clearance <40 mL/min) and in elderly patients. |
| Protein binding | Approximately 30% bound to serum albumin. |
| Volume of Distribution | Volume of distribution is 3.5 L/kg (range 3.2–3.9 L/kg), indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability is approximately 80% (range 75–90%) due to minimal first-pass hepatic metabolism. |
| Onset of Action | Oral: 1–2 hours for beta-blockade effect on heart rate; maximal antihypertensive effect may require 1–2 weeks of therapy. |
| Duration of Action | Duration of beta-blockade (reduction in exercise-induced tachycardia) persists for 24 hours after single oral dose, supporting once-daily dosing. Antihypertensive effect is sustained over 24 hours. |
Adults: Initial dose 2.5-5 mg orally once daily, titrate to 10 mg once daily; maximum 20 mg once daily.
| Dosage form | TABLET |
| Renal impairment | GFR <40 mL/min: Initially 2.5 mg orally once daily; titrate cautiously. GFR <20 mL/min: Not recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B or C: Use with caution; consider starting at 2.5 mg once daily. |
| Pediatric use | Safety and efficacy not established; not recommended for use in children. |
| Geriatric use | Elderly: Start at 2.5 mg orally once daily; titrate slowly due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Calcium channel blockers like verapamil may cause bradycardia and heart failure Abrupt withdrawal may exacerbate angina pectoris or cause myocardial infarction.
| Breastfeeding | Excreted into breast milk in small amounts (M/P ratio approximately 1.9:1). Considered compatible with breastfeeding but monitor infant for bradycardia and hypotension. Use lowest effective dose. |
| Teratogenic Risk | Pregnancy Category C. First trimester: No adequate human studies; animal studies show embryotoxicity at high doses. Second and third trimesters: Risk of fetal bradycardia, hypoglycemia, and growth restriction due to beta-blockade. Use only if potential benefit outweighs risk. |
■ FDA Black Box Warning
No FDA boxed warning.
| Common Effects | heart failure |
| Serious Effects |
Cardiogenic shock, overt heart failure (unless adequately controlled), sinus bradycardia, second- or third-degree AV block (without pacemaker), severe peripheral arterial disease, hypersensitivity to bisoprolol.
| Precautions | Abrupt withdrawal may exacerbate angina or precipitate myocardial infarction; may mask signs of hypoglycemia or thyrotoxicosis; caution in bronchospastic disease, peripheral vascular disease, and renal impairment. |
| Food/Dietary | Avoid excessive alcohol intake; may increase hypotensive effect. No specific food restrictions. Maintain consistent dietary habits, especially regarding salt intake, to avoid BP fluctuations. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of heart failure. Fetal monitoring for growth restriction and bradycardia. Neonatal monitoring for hypoglycemia and bradycardia after delivery. |
| Fertility Effects | No direct evidence of impaired fertility in humans. Beta-blockers may rarely cause erectile dysfunction in males, but no specific effect on female fertility reported. |
| Clinical Pearls | Do not abruptly discontinue; taper over 1-2 weeks to avoid rebound hypertension/angina. Use with caution in bronchospastic disease; cardioselectivity is dose-dependent and lost at higher doses. Monitor heart rate and blood pressure; adjust dose to achieve resting heart rate of 55-60 bpm in stable heart failure. Contraindicated in severe bradycardia, heart block, cardiogenic shock, and decompensated heart failure. May mask symptoms of hypoglycemia in diabetics. Reduce dose in severe hepatic impairment. |
| Patient Advice | Take exactly as prescribed every day, preferably in the morning, with or without food. · Do not stop taking suddenly; withdrawal can cause serious heart problems. · Monitor for slow heartbeat, dizziness, or fainting; report these to your doctor. · Avoid driving or operating heavy machinery until you know how the drug affects you. · Tell your doctor if you have asthma, COPD, diabetes, or thyroid disease. · This drug may mask signs of low blood sugar; check blood glucose regularly if diabetic. · Inform all healthcare providers you are taking this medication before surgery. |